Matinas BioPharma

MTNB

Market cap $9.66M

Overview Fund Activity

1.74 USD

+0.04

2.35%

At close Updated Sep 17, 10:01 AM EDT

1 day

2.35%

5 days

4.82%

1 month

1.75%

3 months

90.37%

6 months

219.27%

Year to date

195.92%

1 year

-51.53%

5 years

-95.63%

10 years

-99.1%

About: Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.

Employees: 34

Healthcare Drug Manufacturers - General

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

53% more capital invested

Capital invested by funds: $166K [Q1] → $254K (+$87.6K) [Q2]

0.86% less ownership

Funds ownership: 6.29% [Q1] → 5.43% (-0.86%) [Q2]

4% less funds holding

Funds holding: 25 [Q1] → 24 (-1) [Q2]

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

See Fund Rankings

Financial journalist opinion

Neutral

GlobeNewsWire

6 months ago

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the “Effective Date”).

Neutral

GlobeNewsWire

7 months ago

Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

BEDMINSTER, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (the “Company”) today announced that the Company entered into a securities purchase agreement (the “Agreement”) with a certain group of investors (the “Investors”), pursuant to which they agreed to purchase from the Company 3,300 shares of Series C Convertible Preferred Stock (the “Preferred Stock”) and warrants to purchase up to 11,262,808 shares of common stock at a purchase price of $1,000 per share of Preferred Stock and accompanying warrants for aggregate gross proceeds of $3.3 million before deducting offering expenses payable by the Company.

Neutral

GlobeNewsWire

7 months ago

Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair

BEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of Evelyn D'An to its Board of Directors as an independent director and Chair of the Audit Committee, effective Wednesday, February 5, 2025.

Neutral

GlobeNewsWire

8 months ago

Matinas BioPharma Receives NYSE Noncompliance Notice

BEDMINSTER, N.J. , Jan. 10, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that on January 6, 2025, it received a NYSE American LLC notice indicating that the Company has fallen below certain NYSE American continued listing standards because it failed to hold its annual meeting of stockholders for the fiscal year ending on December 31, 2024, as set forth in Section 704 of the NYSE American Company Guide.

Neutral

GlobeNewsWire

10 months ago

Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction

BEDMINSTER, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that negotiations under the previously disclosed non-binding term sheet regarding global rights to MAT2203, its oral formulation of amphotericin B, have been terminated following notification from the prospective partner. As a result, Matinas has implemented an 80% workforce reduction effective immediately, eliminating 15 positions including three members of senior management, and has ceased all product development activities to conserve cash.

Neutral

Seeking Alpha

1 year ago

Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call Transcript

Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Jody Cain – LHA Investor Relations Jerry Jabbour – Chief Executive Officer Keith Kucinski – Chief Financial Officer Terri Matkovits – Chief Development Officer Conference Call Participants Scott Henry – Alliance Global Partners Joanne Lee – Maxim Group Operator Welcome to the Matinas BioPharma Second Quarter 2024 Financial Results Conference Call. Currently all participants are in a listen-only mode.

Neutral

GlobeNewsWire

1 year ago

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update

Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections

Neutral

GlobeNewsWire

1 year ago

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024

BEDMINSTER, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report second quarter 2024 financial results after market close on Wednesday, August 14, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Neutral

GlobeNewsWire

1 year ago

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful treatment of a 22-year-old male with polymicrobial necrotizing fasciitis (flesh-eating disease) that involved drug-resistant Lichtheimia, an angio-invasive species of the fungus Mucorales. This patient was treated at New York Presbyterian/Weill Cornell Medical Center and was discharged after just six weeks of treatment with MAT2203, Matinas' oral formulation of the potent antifungal amphotericin B. The patient was treated under Matinas' Compassionate/ Expanded Use Access Program by Sharan Yadav, MD, Infectious Disease Fellow.

Neutral

GlobeNewsWire

1 year ago

Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S.

BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its oral formulation of the potent antifungal amphotericin B, will be featured in a fireside chat with David S.

See News Rankings

Charts implemented using Lightweight Charts™

Matinas BioPharma MTNB Market cap $9.66M

Fund manager confidence

53% more capital invested

0.86% less ownership

4% less funds holding

20% less repeat investments, than reductions

25% less first-time investments, than exits

Financial journalist opinion

Matinas BioPharma

MTNB

Market cap $9.66M